Results 171 to 180 of about 1,702,455 (203)

Thrombopoietin Receptor Agonists

2017
Thrombopoietin receptor agonists (TPO-RAs) should be considered for the treatment of “refractory” autoimmune thrombocytopenia (ITP). In contrast to other medications, TPO-RAs increase platelets via stimulating the production of megakaryocytes/platelets in the bone marrow. This chapter has dealt with the mechanism, efficacy, and safety of TPO-RAs.
openaire   +1 more source

Pyrimidine benzamide-based thrombopoietin receptor agonists

Bioorganic & Medicinal Chemistry Letters, 2007
A series of pyrimidine benzamide-based thrombopoietin receptor agonists is described. The lead molecule contains a 2-amino-5-unsubstituted thiazole, a group that has been associated with idiosyncratic toxicity. The potential for metabolic oxidation at C-5 of the thiazole, the likely source of toxic metabolites, was removed by substitution at C-5 or by ...
Lawrence A, Reiter, Chakrapani, Subramanyam, Emilio J, Mangual, Christopher S, Jones, Marc I, Smeets, William H, Brissette, Sandra P, McCurdy, Paul D, Lira, Robert G, Linde, Qifang, Li, Fangning, Zhang, Amy S, Antipas, Laura C, Blumberg, Jonathan L, Doty, James P, Driscoll, Michael J, Munchhof, Sharon L, Ripp, Andrei, Shavnya, Richard M, Shepard, Diana, Sperger, Lisa M, Thomasco, Kristen A, Trevena, Lilli A, Wolf-Gouveia, Liling, Zhang   +23 more
openaire   +2 more sources

Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia

Hämostaseologie, 2019
AbstractManagement of patients with corticosteroid-refractory immune thrombocytopaenia (ITP) possesses a significant challenge to practitioners. Until recently, options included splenectomy and immunosuppression. With improved knowledge of both thrombopoiesis and the pathophysiology of ITP, novel drug development with thrombopoietin-receptor agonists ...
openaire   +2 more sources

Mechanisms and therapeutic prospects of thrombopoietin receptor agonists

Seminars in Hematology, 2019
The second-generation thrombopoietin (TPO) receptor agonists eltrombopag and romiplostim are potent activators of megakaryopoiesis and represent a growing treatment option for patients with thrombocytopenic hematological disorders. Both TPO receptor agonists have been approved worldwide for the treatment of children and adults with chronic immune ...
James Bussel, Austin Kulasekararaj, Nichola Cooper, Amit Verma, Ulrich Steidl, John W. Semple, Britta Will   +6 more
openaire   +2 more sources

Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease

Seminars in Thrombosis and Hemostasis, 2020
AbstractThrombocytopenia is one of the most common hematologic complications in cirrhosis. Despite limited data linking platelet count and bleeding risk in patients with cirrhosis, the use of platelets transfusions for invasive procedures has been a common practice. Recently, thrombopoietin (TPO) receptor agonists have been approved for use in patients
Saro, Khemichian, Norah A, Terrault
openaire   +2 more sources

Update on the Use of Thrombopoietin-Receptor Agonists in Pediatrics

Hämostaseologie
Abstract This review summarizes the rationale and current data on the use of thrombopoietin receptor agonists (TPO-RAs) for treating severe thrombocytopenia in infants, children, and adolescents. It focuses on substances that have been approved by the U.S.
Jennifer, Gebetsberger, Werner, Streif, Christof, Dame   +2 more
openaire   +2 more sources

Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist

Experimental Hematology, 2005
Peptide and other small molecule agonists have been described for several cytokines and growth factors. Hydrazone compounds described here as thrombopoietin receptor agonists were identified as activating STAT proteins in a Tpo responsive cell line.STAT activation and analysis of signal transduction pathways in cell lines and normal human platelets was
Connie L, Erickson-Miller, Evelyne, DeLorme, Shin-Shay, Tian, Christopher B, Hopson, Kenneth, Stark, Leslie, Giampa, Elizabeth I, Valoret, Kevin J, Duffy, Juan L, Luengo, Jon, Rosen, Stephen G, Miller, Susan B, Dillon, Peter, Lamb   +12 more
openaire   +2 more sources

Cytomegalovirus‐associated thrombocytopenia treated with thrombopoietin receptor agonist

Internal Medicine Journal, 2016
Symptomatic cytomegalovirus (CMV) in immunocompetent individuals is an uncommon, yet recognised, phenomenon. This report discusses a case of CMV‐associated thrombocytopenia refractory to immunomodulation and antivirals. Ultimately, a clinicopathological response was attained with eltrombopag.
J. D. Simpson, G. V. Matthews, T. A. Brighton, J. E. Joseph   +3 more
openaire   +2 more sources

Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine

Science, 1997
Two families of small peptides that bind to the human thrombopoietin receptor and compete with the binding of the natural ligand thrombopoietin (TPO) were identified from recombinant peptide libraries. The sequences of these peptides were not found in the primary sequence of TPO.
S E, Cwirla, P, Balasubramanian, D J, Duffin, C R, Wagstrom, C M, Gates, S C, Singer, A M, Davis, R L, Tansik, L C, Mattheakis, C M, Boytos, P J, Schatz, D P, Baccanari, N C, Wrighton, R W, Barrett, W J, Dower   +14 more
openaire   +2 more sources

Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies

Pediatric Blood & Cancer
ABSTRACT Background Thrombopoietin receptor agonists (TPO‐RAs) have demonstrated efficacy in treating clinically significant thrombocytopenia, including chemotherapy‐induced thrombocytopenia in adults. However, data regarding their safety and efficacy in pediatric, adolescents, and young adult (
Amanda E. Marinoff, Allyson Thrall, Kathryn Aaronson, Benjamin S. Braun, Maria I. Castellanos, Julia Chu, Michelle Hermiston, Benjamin J. Huang, Anya Levinson, Erica Southworth, Beth Apsel Winger, Adam Olshen, Elliot Stieglitz   +12 more
openaire   +2 more sources